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The preparation and characterization of films and nanofibers with carvedilol as a poorly water-
soluble drug in poly (ethylene oxide) (PEO) polymer were investigated. Films are prepared by 
solution casting method, and nanofibers by electrospinning from a polymer solution. Water and 
mixture of ethanol and water were used as solvents. FT-IR analysis of the samples showed that 
there was no interaction between the polymer and the drug substance. DSC analysis revealed that 
carvedilol was dissolved in the polymer and influenced the degree of crystallinity of PEO. 
Carvedilol release rate for all of the formulations was increased in comparison with pure 
carvedilol. Significant differences in the rate of release of carvedilol from the films and 
nanofibers were observed. Field Emission Scanning Electron Microscope (FESEM) images of the 
obtained fiber was revealed the dependence of the fiber diameter of formulation and 
electrospinning process parameters, and consequently influence the amount and distribution of 
carvedilol in the encapsulated fibers.  
 
Keywords: nanofibers, oral films, dissolution rate, process parameters, formulation parameters, 
poly (ethylene oxide)  
1. Introduction 
Special attention in recent years is given to the formulation development of poorly soluble 
drugs, since dissolution of poorly soluble drugs is the rate limiting step for drug absorption and 
bioavailability (Löbenberg and Amidon, 2000). A number of alternative technologies have been 
developed to overcome the drawbacks associated with poor aqueous solubility; electrospun 















Electrospinning is a versatile technique through which a variety of constructs can be obtained 
with application in biomedicine (medical prosthesis, tissue scaffolds, wound dressings, drug 
delivery, cosmetics), textiles, electricity and optics, sensors, filtration, catalysis, unconventional 
energy sources and storage cells (Hunley and Long, 2008; Huang et al., 2003). In the field of 
drug delivery and tissue engineering, electrospun polymer nanofibers have gained increasing 
importance because they present several advantages: relatively easy drug entrapment during the 
electrospinning process, obtaining of high loadings if so desired, burst control, stability and 
preservation of drug/growth factor activity, high surface area to volume ratio (which enhances 
drug release) and specific morphology which can be easily controlled during the electrospinning 
process (Agarwal et al., 2008). The polymer fibers are formed from a solution between two 
electrodes bearing electrical charges of opposite polarity. One of the electrodes is placed into the 
solution and the other onto a collector. Once ejected out of a metal needle, the charged solution of 
the jets evaporates to become fibers, which are collected on the collector. The structure and the 
morphology of electrospun polymer materials, be it fibers or particles, are determined by the 
synergistic effects of solution parameters (polymer concentration, solution viscosity and flow 
rate) and electrostatic forces (applied voltage and distance between the needle and collector) 
(Dukali et al, 2014). Immediate or modified drug release can be achieved by the selection of a 
polymer for nanofiber production and the manner of the drug loading. The drug can be either 
incorporated into the polymer matrix of the nanofibers or bound to their surfaces (Huang et 
al.,2003; Meinel et al., 2012; Rošic et al., 2012). Factors that can affect the drug release from 
electrospun fibers are: fiber construct geometry and thickness (Okuda et al., 2009), fiber diameter 
and porosity (Cui et al., 2006; Bertoncelj et al., 2014; Sill and von Recum, 2008), fiber 
composition (Buschle-Diller et al., 2007), fiber crystallinity (Kenawy et al., 2002), fiber swelling 















drug state (Zamani et al., 2010; Xie and Wang, 2006), drug molecular weight (Buschle-Diller et 
al., 2007; Taepaiboon et al., 2006), drug solubility in the release medium (Xie and Buschle-
Diller, 2009), drug–polymer–electrospinning solvent interactions (Chewet al., 2005; Zeng et al., 
2005).  
The solution casting is one of the oldest methods of film production. This method has been 
later replaced with extrusion, pressing and polymer blowing from the melt. However, it is still 
used for preparation of high quality thin films, especially if combined with the spin coating 
method for application to the substrates. The following conditions must be met for this method: 
the polymer must be soluble in a liquid solvent or in water; a solution with the appropriate 
viscosity should be formed; a homogenous film, easily extractable from the mould should be 
formed (Siemann, 2005). 
Carvedilol, nonselective beta blocker, was used as a model drug. It is poorly soluble in water 
(0.583 mg/l at 25 °C) and highly permeable, belonging to the BSC class II (Kalimuthu and 
Yadav, 2011). So far, carvedilol nanofibers, successfully developed by different polymers, have 
been described in literature. Nanofibers obtained by electrospinning from carvedilol solutions 
were obtained using following polymers: poly(butyl methacrylate-co-(2- demethylaminoeethyl) 
methacrylate-co-methyl methacrylate)  - Eudragit
®
 E, poly(methacylic acid-co-methyl 
methacrylate) -  Eudragit
®
 L 100-55, polyvinylpyrrolidone K90 (Baleogh et al., 2015), 
polycaprolactone (Potrč et al., 2015), vinylpyrrolidone-vinyl acetate copolymer - Kollidon
®
 VA 
64 (Balogh et al., 2015). Carvedilol - Eudragit
®
 EPO (poly(butyl methacrylate-co-(2-
dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1)  nanofibers, prepared by melt 
electrospinning were described in literature by (Balogh et al., 2014; Krist of ´ Nagy et al., 2013). 
The solid dispersion methods for BCS class II drugs were developed as pharmaceutical forms in 















form the backbone of solid dispersion formulations increase the solubility and dissolution profile 
of hydrophobic drugs by several mechanisms, such as increased porosity, reduction in 
agglomeration and particle size, improved wettability and solvent access due to increased surface 
area. Good results were obtained with Polyvinylpyrrolidone K30 and Eudragit L100 (Yuvaraja 
and Khaman, 2014 and Lee et. al., 2013.). In this study  the presence of Poly (ethylene oxide) 
(PEO) and Polysorbat 80 increased solvatation (dissolution) of carvedilol  by  surrounding of 
drug molecules with hydrophilic molecules  of PEO and enhancing  wettability of drug molecule 
(Dewan et al., 2012., Hammouda, 2006 and Balogh et al., 2015). In the other manner the 
hydrophobic parts of PEO also tend to attract the similar part from carvedilol molecules. A drug 
is thoroughly dispersed in a water-soluble carrier.  
The aim of this work was formulation, development and evaluation of nanofibers and oral 
films, as potential carriers for carvedilol, produced from PEO polymer solutions. Carvedol/PEO 
solutions, prepared in water or ethanol/water mixture was casted to produce films, or electrospun 
to produce nanofibers. In electrospinning process, flow rate and collector surface area were 
varied. Produced films and nanofibers were evaluated with respect to drug content, degree of 
crystallinity and drug release. Morphology of nanofibers was also observed. Finally, formulation 
with higher drug content (compared to declared) and the fastest drug release will be chosen. 
 
 
2. Materials and methods 
2.1. Materials 
Carvedilol, which was used as a model substance, was Ph. Eur. 8 grade. Polysorbate 80 















with a molecular weight of 600 000 g/mol (Acros Organics, Belgium) was used as a polymer. 
Ethanol (99.5 v/v), which was Ph. Eur. 8 grade, was used as solvent and deionized water (DI) 
(resistance of 18 MΩcm) was used for the preparation of solutions. 
2.2. Methods 
2.2.1. Preparation of nanofibers and films 
The two series of the PEO solutions for electrospinning and solution casting were prepared: 
one was PEO in water; second PEO in ethanol/water mixture (40/60, w/w). Firstly, the amount of 
1 g of PEO was added in 19 ml of deionized water and stirred 12 h. In this solution 0.1 g (0.05 g) 
carvedilol and 0.02 ml of Polysorbat 80 were added and mixed continuously for 24 h. The same 
procedure was used for solution prepared with solvent consisted of ethanol/water mixture (40/60, 
w/w). The complete solubility of carvedilol was achieved  as a consequences of the presence of 
PEO and Polysorbat 80 in the water (Dewan 2012., Hammouda 2006, Balogh 2015, Yang et al, 
2015). 
Prepared solutions was used both for electrospinning (nanofibers) and for solution casting 
(film). 
 Electrospinning process (Electrospinning setup CH-01, Linari Engineering, Italy) was setup as 
follows: a 20 ml plastic syringe with a metallic needle of 1 mm inner diameter was set vertically 
with the syringe pump (R-100E, RAZEL Scientific Instruments); the high-voltage power supply 
(Spellman High Voltage Electronics Corporation, Model: PCM50P120) was set to the voltage of 
28 kV. Distance from the needle tip and collector was 15 cm. The grounded copper collector, 
rectangular shape, overlaid with aluminum foil, was used for collecting nanofibers. Based on the 
screening studies, two process parameters, the surface area of collector and flow rate, were 
chosen and varied. Two collectors of different surface area were used: 121 cm
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(Table 1). The flow rate of the solution was adjusted according to the formulation (Table 1). The 
electrospinning solution was spun in the single needle setup. All equipment was setup in closed 
chemical laboratory draft chamber system ventilated cabinet (Fig 1). 
For the solution casting method, prepared solutions were poured into flat-bottomed Petri 
dishes and dried 48 h at room temperature. 
2.2.2. Carvedilol assay in nanofibers and films 
Carvedilol assay in formulations was done in order to assess amount of carvedilol retained in 
nanofibers and films. The exact amount of nanofibers/films was dissolved in specified amount of 
0.1 M HCl. Carvedilol content was evaluated with UV spectroscopy, on 241 nm, using UV/VIS 
spectrophotometer Evolution 300 (Thermo Fisher Scientific, Cambridge, UK). Carvedilol content 
was expressed in percents, as the ratio between carvedilol content determined in formulation and 
declared content of carvedilol. The results were shown as medium value of three repeated 
measurements for each sample. 
2.2.3. Field Emission Scanning Electron Microscope (FESEM) 
The morphology of nanofibers was obtained using a Field Emission Scanning Electron 
Microscope (FESEM, TESCAN MIRA 3) with fracture surfaces sputtered with gold. 
2.2.4. Fourier-transform infrared spectroscopy (FT-IR) 
FT-IR spectra in the region of 600-4000 cm
-1
 for pure carvedilol and selected formulations, 
were obtained by a Shimadzu IR-Prestige-21 FT-IR spectrometer coupled with a horizontal 
















2.2.5. Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) was applied in order to determine thermal properties 
of carvedilol and selected formulations. Thermal properties were examined at temperatures 
ranging from room temperature up to 150 °C on Mettler–Toledo AG, Analytical, Switzerland, 
DSC 1 under a dry nitrogen atmosphere (flow rate: 100 cm3 min–1) at a heating rate of 10 ºC 
min–1. The sample masses were between 7.3 mg and 11.5 mg. 
The degree of crystallinity, α, of the polymer was calculated from Hm , the heats of melting 








            (1) 
where Hº m  is 213.7 J/g and presents the heat of melting per gram of 100% crystalline PEO, 
(Grkovic et al., 2016). 
2.2.6. In vitro drug release studies  
Rotating paddle apparatus (Erweka DT70, Germany) was used, at rotating speed of 50 rpm. 
900 ml of 0.1 M HCl was used as dissolution medium, at 37 °C. Samples of 4 ml were taken 
from medium at fixed time intervals (10, 20, 30, 45, 60, 90 and 120 minutes). All samples were 
filtered through membrane filter. The concentration of carvedilol was determined with UV/VIS 
spectrophotometer Evolution 300 (Thermo Fisher Scientific, Cambridge, UK). The results were 
shown as medium value of three repeated measurements for each sample. The weight of every 
sample was such that every sample has 25 mg of carvedilol. 
In order to assess an increase in dissolution rate of carvedilol from nanofibers and films, pure 
carvedilol (25 mg) and immediate release tablets of carvedilol (Milenol
®















Hemofarm A.D, Serbia) were compared with developed formulations. Drug release profiles were 
compared using similarity factor (f2) (Moore et al, 1996). 
3. Results and discussion 
3.1. Carvedilol assay in nanofibers and films 
 
The results of carvedilol assay in nanofibers and films are shown in Table 2. It can be observed 
that the content of carvedilol in oral films is in accordance with the declared assay, regardless of 
the type of solvent used (over 92.8%). In nanofibers made by electrospinning, when water was 
used as solvent (F4, F5), high amount of carvedilol was detected (92.4 - 98.4%). However, when 
mixture of ethanol and water was used as solvent (F6, F7), significantly lower assay of carvedilol 
was measured (45.7 - 47%). In the case, the evaporation of ethanol was faster, and part of 
carvedilol was precipitated on collector, not incorporated in fibers.  
Based on obtained results, the water was selected as the most suitable solvent. In following 
experiments (F8, F9, F10), water was used as solvent, with increase in collector size, which 
provided nanofibers with high carvedilol assay (86.32-90.24%). 
Carvedilol assay in nanofibers prepared with PEO, with a mixture of water and ethanol was 
similar as in the study about nanofibers of carvedilol described in literature and prepared with 
polycaprolactone where it was 86-100%. However, the degree of drug incapsulation into films 
















3.2. Field Emission Scanning Electron Microscope (FESEM) 
Figure 2 and Figure 3 show images of F8, F9 and F10 nanofibers with fiber diameter distribution 
based on FESEM imaging (Other figures and histograms are presented in Supplementary data).  
Dimensions and diameter of fibers depend on the viscosity of solutions and process parameters of 
electrospinning – applied voltage, flow rate, collector size and distance between the needle and 
collector. It can be seen on FESEM images that, for different type of solvent used, fibers with 
different diameters are obtained. Obtained fibers have uniform diameter, but, due to instability of 
the process in case F5 drops and bubbles are formed into fibers (See Fig 2. in Supplementary 
data). 
FESEM Image of F4 (Figure 1 in Supplementary data ), which was prepared from water 
solution, shows that produced fibers have medium diameter of 132 nm, and declared carvedilol 
content. FESEM image of formulation produced by electrospinning shows that F5 (Figure 2 in  
Supplementary data) has fibers with medium diameter of 161 nm. Droplets and beads are also 
present, due to nonstationary conditions, so this method can be characterized as a combination of 
electrospinning – electrospraying. However, carvedilol was retained in these beads, resulting in 
high carvedilol loading in formulations, but uneven drug distribution. 
FESEM images of formulations F6 and F7 (Figs. 3 and 4 in Supplementary data), produced 
from ethanol/water mixture, in order to obtain finer fibers with smaller diameter, show that 
obtained fibers have medium diameter of 172 nm and about 50%  reduced carvedilol content 
(45.7%; 47%), due to accelerated evaporation of ethanol and part of carvedilol was precipitated 
on collector. Figures 3 and 4 in Supplementary data show drug agglomeration beyond fibers.  
Figures 2 and 3 show FESEM images of nanofiber formulations F8, F9, and F10.  Produced 















content. It can be observed that obtained fibers have uniform diameter (without droplets and 
beads), with the homogenous distribution of carvedilol (without agglomeration beyond fibers). 
An increase in the diameter of the nanofiber according to an increased flow rate was also 
observed in other studies (Zong et al, 2002; Hardwaj and Kundu, 2010). 
During the electrospinning process, when the polymer jet is ejected and accelerated toward 
the collector, the solvent evaporates rapidly as the high surface area jet travels to the target. As an 
outcome of rapid evaporation of solvent, non-woven filament mats are formed rapidly, and this 
leads to a decrease in drug mobility. When solvent evaporation is complete, drug molecules are 
often “frozen” in the polymer fibers matrix. So, it was important to define electrospinning process 
parametrs to obtain the smooth fiber with dimensions capable to carry the molecules of drugs, 
with no precipitation out of fibers (Yu et al, 2010) .  This condition was achieved in production of 
formulation F8, F9, and F10. In this case the homogeneity of samples is good. 
3.3. Fourier-transform infrared spectroscopy (FT-IR) 
In the FT-IR spectra of pure PEO the peak at 2886 cm
-1
 observed attributed to C-H stretching 
(Fig. 4). The band at 1461 cm
-1




 CH2 belonged to wagging mode. Also, the band at 1277 cm
-1
 was belonged to CH2 
twisting mode, and for C-O-C stretching mode the peak was observed at 1093 cm
-1










(Gondaliya et al., 2011). 
An FT-IR spectrum of pure carvedilol showed the peaks 3446 cm
–1
 (N-H, stretching), 2926 
cm
–1
 (C-H, stretching), 2842.60 cm
–1
 (C-H, stretching) and 1094cm
–1
 (C-O, stretching). These 
peaks can be considered as characteristic peaks of carvedilol (Dewan et al., 2012; Bal et al., 















The FT-IR spectra for film and nanofibers also have those bands and revealed that there no 
interaction between carvedilol, Polysorbate 80 and PEO. The peak at 1732 cm
-1
 could be 
attributed to the carbonyl group of Polysorbate 80. 
3.4. Differential scanning calorimetry (DSC) 
The results of DSC analysis of pure carvedilol, PEO and PEO/carvedilol films and fibers from 
different solution are presented in Figure 5a. The melting peak of crystalline carvedilol was 
obtained at 117 ºC. This peak was not detected in films and fiber samples, suggesting the 
amorphous form of carvedilol, which was dissolved and there was not there as crystalline phase 
(Balogh et al., 2015; Gao et al., 2005). Evaporation of solvent  in electrospinnig processes are 
completed in very short time. So, there was no time for the drug molecules to form crystal 
lattices, and thus the drug complexed with the polymer on a molecular scale. 
For PEO (as received) the melting point was at 71.34 ºC (Ibrahim and Johan, 2012; Meka et 
al., 2014). Melting peaks of films and fibers with added carvedilol to PEO solutions was slightly 
changed due influence of carvedilol and surfactant Polysorbate 80 (Girdthep et al., 2011). 
DSC curves of films with PEO polymers in different solvents (water or water/ethanol), 
both without and with Polysorbate 80, are shown on Figure 5b. From this diagram it could be 
seen that Tm of pure PEO after solution in water and mixing solvents is higher than for PEO 
powder (Table 3, Figure 5). After that, added Polysorbate 80 as surfactant was acting as 
plasticizer and Tm was decreased. It is a well-established and proven fact that a lamellar crystal is 
the fundamental structural form by which polymers most generally crystallize, a feature true for 
the vast majority of semicrystalline polymers crystallized from the bulk (i.e. from solution or 
from melt). Crystallinity of PEO was influenced with solvents and Polysorbate 80 too. The 















and growth of crystal was suppressed by difficult ordering of molecules dividing and oriented in 
hydrophobic – hydrophilic  solvatation manner. 
Crystallinity of polymers, represented by degree of crystallinity (α), is ratio of amount 
of crystalline region in polymer structure with respect to amorphous content. In crystal region 
polymers have ordered structure and molecules are arranged in a regular, periodic manner., while 
in the amorphous region the the structure is quite random. The degree of crystallinity has a big 
influence on mechanical properties, density, transparency, diffusion and hence 
solubility. Degrees of crystallinity for PEO powder (as received), films F2 and F3, as well as 
fibers F5 and F6 are presented in Table 3. Crystallinity of PEO obtained from dispersions was 
decreased because there was a difficulty of PEO molecules to order in crystal with presence of 
solvent molecules. Also, with the adding of Polysorbate 80 in solution the conditions for 
crystallization of PEO was changed. It is obvious that degree of crystallinity of the films is higher 
than for electrospun fibers. During electrospinnig, the molecules that are aligned along the fiber 
axis have less time to realign themselves, leading to less favorable packing. For most semi-
crystalline polymers, the stretched chains under high elongation rate do not get enough time to 
form crystalline lamellae, which yields lower crystallinity. Hence, the crystallinity in the fibers is 
thereby influenced by the rate of solvent evaporation (Baji et al., 2010; Huang et al., 2003; 
Greiner and Wendorff, 2007). Degrees of crystallinity for fibers (and films) with carvedilol from 
the aqueous solution are lower compared to fibers prepared with ethanol/water solutions. 
3.5. In vitro drug release  
Carvedilol release from nanofibers and films is presented in Table 4. It can be observed from 
the results that significant increase in dissolution rate of carvedilol was obtained from all 















commercial immediate release carvedilol tablets. From all formulations, except F7, more then 
80% of carvedilol was released in 30 minutes.  
Comparing dissolution profiles and calculating similarity factors (f2) it was observed that 
dissolution profiles from all formulations are significantly different from dissolution profiles of 
pure carvedilol (f2 <50). The percentage of carvedilol from the prepared nanofibers was 
significantly higher, compared to nanofibers of carvedilol prepared with polycaprolactone (Potrč 
et al, 2015). Potrč et al. have formulated nanofibers from which 15-30% carvedilol has been 
created in 1 h, whereas we achieved a dissolution of over 90% of carvedilol in 1 h (Potrč et al, 
2015). 
Comparing dissolution profiles of formulations F1-F3 with different amount of carvedilol in 
the film (5% or 10%), it was observed that, when water was used as solvent (F1 and F2), 
dissolution profiles are significantly different (f2- 38.86). This probably occurs due to low 
solubility of carvedilol in water. As a result, with increase in amount of carvedilol (in 
formulations where water was used as a solvent), dissolution rate of drug decreases. Nanofibers 
prepared with water, with different amount of carvedilol (F4 and F5), shown the same trend as 
films, and significant difference in dissolution rate was observed (f2- 37.36). The highest 
dissolution rate was achieved with nanofibers with lower drug loading, probably for the same 
reason which was described at film formulations. When comparing different types of solvents 
used in formulation of oral films, significant difference in dissolution rate of carvedilol was 
observed at highest carvedilol assay in formulation - formulations F2 and F3 (f2- 46.07). This 
probably occurs because carvedilol can be fully dissolved only in mixture of ethanol and water 
with Polysorbat 80 and PEO, becoming instantly available for dissolution from the formulation.  
Comparing drug dissolution profiles from electrospun nanofibers and oral films made with 















difference in dissolution rate of carvedilol, regardless the amount of drug in formulations (F1 and 
F4 (f2 - 66.18); F2 and F5 (f2 - 60.04)).Changing the collector size, significant difference in 
dissolution rate of carvedilol was observed, when oral films and nanofibers prepared with water 
as solvent, and with 10% of carvedilol in formulation.  Similarity factors were  35.09, 36.37, 
39.64  for formulations F2 and F8; F2 and F9; F2 and F10, respectively. In this case, the higher 
dissolution rate was achieved from nanofibers. A lower percentage of drug dissolutions from 
films compared to fibers correlates with the results described in literature (Kenawy et al, 2009; 
Potrč et al, 2015). Differences in dissolution rate of carvedilol, made with changes in collector 
size, are probably the consequence of nanofibers diameter change, which was confirmed with 
FESEM analysis. Change in collector surface area, when using water as solvent, and with flow 
rate at 1 ml/h (F5 and F10), results in significant differences in dissolution rate of carvedilol, 
where the higher dissolution rate was achieved when bigger collectors were used (f2 - 17.87). The 
higher dissolution rate of carvedilol probably was a consequence of differences in size and 
structure of nanofibers, also more uniform distribution of drug, which was confirmed by FESEM 
analysis. It was not observed any significant difference in dissolution rate of carvedilol when 
mixture of water and ethanol was used as solvent, depending on flow rate used during preparation 
(F6 and F7 (f2 - 78.96)). Also, in the case of higher surface area of collector, increasing of the 
flow rate  do not affect the dissolution rate of carvedilol (F8 and F9 (f2 - 73.22); F8 and F10 (f2 - 
69.51); F9 and F10 (f2 - 70.23)). During preparation of nanofibers flow rate can be increased, in 
order to achieve higher income, whilst preserving dissolution rate of carvedilol.  
In F8, F9 and F10 fibers, significant improvement in dissolution rate was achieved, compared 
to F2 film formulation and F5 nanofiber formulation. This is probably the consequence of the 
same carvedilol content and it’s uniform distribution in F8, F9 and F10 fibers. This can be 















becomes immediately available for dissolution. F5 formulation has beads, and therefore uneven 
distribution of carvedilol, so the drug is not available for dissolution immediately after contact 
with dissolution medium. In oral film formulations, certain time is needed for dissolution of 
carvedilol, due to slower film disintegration and slower diffusion of the medium. Based on this 
comparison, it can be concluded that with increase in collector size, diameter of fibers increases, 
the distribution of carvedilol is more uniform, without beads, all of which leads to increase in 
dissolution rate of carvedilol. 
4. Conclusion 
Prepared films and nanofibers with carvedilol significantly increase the dissolution rate of 
carvedilol. FT-IR analysis of obtained samples shows that interaction between polymer and drug 
did not occur. DSC analysis revealed the dissolution of carvedilol in PEO and change of Tm  of 
PEO according formulation. Also, it was revealed that degree of PEO crystallinity  of fibers was 
lower than films, because of faster solvent evaporation. FESEM analysis and content 
determination of drug in nanofibers show that, when mixture of ethanol and water is used as 
solvent, significant loss of carvedilol content from nanofibers occurs. Based on aforementioned, 
it can be concluded that mixture of ethanol and water is not suitable as solvent for nanofibers 
production by electrospinning method. Significant differences between dissolution rate of 
carvedilol from the films and nanofibers were not observed, when smaller size collectors were 
used. When bigger collectors were used, significant difference in dissolution rate of carvedilol 
was observed, wherein the higher dissolution rate was achieved from nanofibers formulations. 
This study is of exceptional significance in the impact assessment of process and formulation 
parameters on the characteristics of nanofibers produced by electrospinning process. Formulation 















min) as well as high drug loading (86.32 %), uniform carvedilol distribution inside the fibers, 
satisfactory fiber dimensions, together with high flow rate, which all lead to high income. The 
nanofibers formulated on this way in future shoud be defined into final pharmaceutical form 
(tablet or capsule), in order to increase bioavailability of carvediol compared to the pure drug.  
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Table 1 Composition of films (F1-F3) and nanofibers (F4-F10), preparing method, collector 
surface areas and flow rate (PEO - poly (ethylene oxide); SC - solution casting; ES - 
electrospinning). 
Table 2 Results of carvedilol assay in formulations F1-F10 presented as percent of declared 
content 
Table 3 Results of DSC analysis: melting point (Tm) and degree of crystallinity (α). 




















F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
films nanofibers 
Carvedilol, with respect to 
PEO, % 
5 10 10 5 10 10 10 10 10 10 
Solvent I: Water + +  + +   + + + 
Solvent II: Ethanol/ Water 
(40/60, w/w) 
  +   + +    
Preparing method SC SC SC ES ES ES ES ES ES ES 




   121 121 121 121 1156 1156 1156 

















Formulation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 


















Formulation Tm, ºC α, % 
Carvedilol 120.68  
PEO 71.34 68.33 
F2 - film-aqueous solution 10% 71.71 38.94 
F3 - film- aqueous/ethanol solution 10% 70.48 44.56 
F5 - fibers - aqueous solution 10% 66.77 26.82 
F6 - fibers- aqueous/ethanol solution 10%* 68.00 38.67 
PEO-film aqueous solution 73.20 19.74 
PEO-film aqueous/ethanol solution 72.59 17.04 
PEO+Polysorbat 80-film aqueous solution 68.75 16.24 
PEO+Polysorbat 80-film aqueous/ethanol solution 71.46 13.11 



























F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
10 68.27 36.57 63.47 67.19 28.21 43.68 43.88 79.80 76.45 72.00 18.32 64.56 
20 88.86 59.04 75.18 78.80 59.59 68.66 67.18 88.20 87.57 82.08 27.54 80.33 
30 92.32 85.16 83.96 88.35 80.91 80.25 76.34 88.90 88.27 86.40 30.13 83.46 
45 92.76 92.60 91.20 93.28 82.00 85.93 82.02 91.00 88.96 89.28 34.91 87.75 
60 93.75 94.20 92.05 96.06 87.98 91.47 88.99 93.81 90.35 93.89 37.12 88.69 
90 93.88 94.21 92.39 97.70 88.60 93.56 91.94 96.63 91.74 96.48 41.20 90.12 
















Fig. 1. Photographs of electrospinning setup. 
Fig. 2. FESEM Images of a) F8 (nanofibers with water and 10% carvedilol, flow rate 0.2 ml/h); 
b) F9 (nanofibers with water and 10% carvedilol, flow rate 0.5 ml/h) and c) F10 (nanofibers with 
water and 10% carvedilol, flow rate 1 ml/h). 
Fig. 3. FESEM histograms of a) F8 (nanofibers with water and 10% carvedilol, flow rate 0.2 
ml/h); b) F9 (nanofibers with water and 10% carvedilol, flow rate 0.5 ml/h) and c) F10 
(nanofibers with water and 10% carvedilol, flow rate 1 ml/h). 
Fig. 4. FT-IR of PEO, carvedilol, film (formulation F2 (water, 10% carvedilol (Film-aq-10))) and 
fibers (formulation F10 (water, 10% carvedilol (Fib-aq-10))) with carvedilol. 
Fig. 5.  a) DSC curves of PEO, carvedilol (Car), film (formulation F2 (water, 10% carvedilol 
(Film-aq-10)) and formulation F3 (water/ethanol, 10% (Film-aq/et-10))) and fibers (formulation 
F10 (water, 10% carvedilol (Fib-aq-10)) and formulation F6 (water/ethanol, 10% carvedilol 
declared, 4.57% assay (Fib-aq/et-10))) . 
b) DSC curves of films: PEO in water (PEO-aq); PEO in mixture water/ethanol (PEO-aq/et), 
PEO in water with Polysorbate 80 (PEO+P-aq); PEO in mixture water/ethanol with Polysorbate 
80 (PEO+P-aq/et). 
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